Combined expression of p161NK4a and p27Kip1, but not p21WAF1, differentiates endocervical from endometrial adenocarcinoma

Anal Quant Cytol Histol. 2011 Oct;33(5):283-8.

Abstract

Objective: To differentiate endocervical adenocarcinoma (ECA) from endometrial adenocarcinoma (EMA) using p16INK4a, p21WAF1 and p27Kip1.

Study design: The distinction between ECA and EMA can be problematic on small biopsies or in advanced tumor stage. Immunohistochemistry was done on paraffin-embedded tissue sections of hysterectomy specimens of all types of ECA and EMA. Protein expression was scored as 0 to 3 depending on percentage of positive tumor cells.

Results: A total of 40 ECA and 92 EMA cases were examined. For ECA, 32 of 40 (80.0%) cases had score of 3 with p16INK4a expressions; 23 of 92 (25.0%) cases of EMA had similar scores. For p21WAF1 expressions, 28 of 40 (70.0%) ECA cases scored 3 and 72 of 82 (78.2%) of EMA had a similar score. p27Kip1 scored 3 in 17 of 40 (42.5%) ECA cases; only 14 of 92 (15.2%) cases of EMA cases had such a score. We observed significant higher expressions of p16INK4a (p < 0.001) and p27Kip1 (p = 0.001) in ECA than in EMA. Combined positive expression and combined negative expression of p16INK4a and p27Kip1 strongly differentiates ECA from EMA (< 0.0001).

Conclusion: ECA could be strongly differentiated from EMA based on the expressions of combined p16INK4a and p27Kip1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma, Clear Cell / metabolism
  • Adenocarcinoma, Clear Cell / pathology
  • Adult
  • Aged
  • Biomarkers, Tumor / metabolism
  • Biopsy
  • Carcinoma, Adenosquamous / metabolism
  • Carcinoma, Adenosquamous / pathology
  • Carcinoma, Endometrioid / metabolism*
  • Carcinoma, Endometrioid / pathology
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism*
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism*
  • Cyclin-Dependent Kinase Inhibitor p27 / metabolism*
  • Cystadenocarcinoma, Serous / metabolism
  • Cystadenocarcinoma, Serous / pathology
  • Diagnosis, Differential
  • Endometrial Neoplasms / metabolism*
  • Endometrial Neoplasms / pathology
  • Female
  • Humans
  • Immunohistochemistry / methods
  • Middle Aged
  • Uterine Cervical Neoplasms / metabolism*
  • Uterine Cervical Neoplasms / pathology

Substances

  • Biomarkers, Tumor
  • CDKN1A protein, human
  • CDKN1B protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclin-Dependent Kinase Inhibitor p27